Article thumbnail

Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice

By Mario Merlini, Eric P. Meyer, Alexandra Ulmann-Schuler and Roger M. Nitsch

Abstract

Cerebrovascular lesions related to congophilic amyloid angiopathy (CAA) often accompany deposition of β-amyloid (Aβ) in Alzheimer’s disease (AD), leading to disturbed cerebral blood flow and cognitive dysfunction, posing the question how cerebrovascular pathology contributes to the pathology of AD. To address this question, we characterised the morphology, biochemistry and functionality of brain blood vessels in transgenic arctic β-amyloid (arcAβ) mice expressing human amyloid precursor protein (APP) with both the familial AD-causing Swedish and Arctic mutations; these mice are characterised by strong CAA pathology. Mice were analysed at early, mid and late-stage pathology. Expression of the glucose transporter GLUT1 at the blood–brain barrier (BBB) was significantly decreased and paralleled by impaired in vivo blood-to-brain glucose transport and reduced cerebral lactate release during neuronal activation from mid-stage pathology onwards. Reductions in astrocytic GLUT1 and lactate transporters, as well as retraction of astrocyte endfeet and swelling consistent with neurovascular uncoupling, preceded wide-spread β-amyloid plaque pathology. We show that CAA at later disease stages is accompanied by severe morphological alterations of brain blood vessels including stenoses, BBB leakages and the loss of vascular smooth muscle cells (SMCs). Together, our data establish that cerebrovascular and astrocytic pathology are paralleled by impaired cerebral metabolism in arcAβ mice, and that astrocyte alterations occur already at premature stages of pathology, suggesting that astrocyte dysfunction can contribute to early behavioural and cognitive impairments seen in these mice

Topics: Original Paper
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3168476
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease.
  2. (1998). Alzheimer’s b-amyloid vasoactivity: identification of a novel b-amyloid conformational intermediate.
  3. (2003). Alzheimer’s disease and angiogenesis.
  4. (1998). Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer’s disease.
  5. (2007). Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice.
  6. (1999). An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons.
  7. (2010). Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain.
  8. (2011). Astrocyte-neuron metabolic relationships: for better and for worse.
  9. (2009). b-amyloid, blood vessels, and brain function.
  10. (2008). Basal and stimulated lactate fluxes in primary cultures of astrocytes are differentially controlled by distinct proteins.
  11. (2008). Bordey A
  12. (2000). Cell-specific localisation of monocarboxylate transporters, MCT1 and MCT2, in the adult mouse brain revealed by double immunohistochemical labeling and confocal microscopy.
  13. (2008). Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease.
  14. (2009). Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.
  15. (2004). Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer’s disease pathogenesis.
  16. (2001). Cerebral microvascular pathology in aging and Alzheimer’s disease.
  17. (2004). Correlation between local monocarboxylate transporter 1 (MCT1) and glucose transporter 1 (GLUT1) densities in the adult rat brain.
  18. Cuzzoni G et al (2005) Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer’s disease: recovering effect with insulin and DHEA sulfate. Karg Demen Ger Cog Dis
  19. (1998). de la Sayette V et al
  20. (1994). Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease.
  21. Dewachter I et al (2000) Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons.
  22. (2010). Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-b variants in cells composing the cerebral vessel walls.
  23. (2002). Differential distribution of laminins in Alzheimer disease and normal human brain tissue.
  24. (2005). Differential effects of oligomeric and fibrillar amyloid-b1-42 on astrocyte mediated inflammation.
  25. (1996). Dystroglycan in the cerebellum is a laminin a2-chain binding protein at the glial-vascular interface and is expressed in Purkinje cells.
  26. (2006). Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis.
  27. Eckman CB et al (2001) The ‘‘Arctic’’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Ab protofibril formation.
  28. et al (2003) Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signalling-dependent mechanism.
  29. (1988). Extracellular lactic acid as an indicator of brain metabolism: continuous on-line measurement in conscious, freely moving rats with intrastriatal microdialysis.
  30. (1976). Extravasation, spread and cellular uptake of Evans blue-labelled albumin around a reproducible small stab-wound in the rat brain.
  31. (2009). Formation of amyloid-b oligomers in brain vascular smooth muscle cells transiently exposed to iron-induced oxidative stress.
  32. (2007). Glial regulation of the cerebral microvasculature.
  33. (2001). Glucose and lactate metabolism during brain activation.
  34. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilisation.
  35. (2009). Hereditary and sporadic forms of Abcerebrovascular amyloidosis and relevant transgenic mouse models.
  36. (2005). How astrocytes feed hungry neurons.
  37. Hozumi K et al (2007) Identification of multiple amyloidogenic sequences in laminin-1.
  38. (2007). Intracellular Ab and cognitive deficits precede b-amyloid deposition in transgenic arcAb mice.
  39. (2006). Lactate: the ultimate cerebral oxidative energy substrate?
  40. (1991). Laminin and s-laminin are produced and released by astrocytes, Schwann cells and schwannomas in culture.
  41. (2009). Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer’s disease.
  42. (2009). Losing your nerves? Maybe it’s the antibodies. Nat Rev Immunol 9:449–456
  43. (2009). Loss of astrocyte polarity marks blood– brain barrier impairment during experimental autoimmune encephalomyelitis.
  44. (2009). Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy.
  45. (2009). Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging.
  46. Mirek H et al (2006) The ‘‘perivascular pump’’drivenbyarterial pulsationisa powerfulmechanismforthe distribution of therapeutic molecules within the brain. Mol Ther 14:69–78
  47. (2009). Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease.
  48. (2009). Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease.
  49. (2005). Neurovascular mechanisms of Alzheimer’s neurodegeneration.
  50. (1994). Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease.
  51. (2009). Padovani A
  52. (2011). Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model.
  53. (2010). Reactive astrocytes give neurons less support: implications for Alzheimer’s disease. Neurobiol Aging
  54. (1989). Reduced glucose transporter at the blood–brain barrier and in cerebral cortex in Alzheimer’s disease.
  55. (2009). Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer’s disease.
  56. (2006). Ro ¨nnba ¨ck L, Hansson E
  57. (1993). Secretion of amyloid precursor protein and laminin by cultured astrocytes is influenced by culture conditions.
  58. So ¨derberg L et al (2009) Amyloid b protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice.
  59. (2001). Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy.
  60. (2007). Supply and demand in cerebral metabolism: the role of nutrient transporters.
  61. (2008). The blood–brain barrier in health and chronic neurodegenerative disorders.
  62. (2005). The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded.
  63. (2005). The production and localization of laminin in cultured vascular and corneal endothelial cells.
  64. (2010). The vascular hypothesis of Alzheimer’s disease: bench to bedside and beyond.
  65. (2009). Vascular amyloid alters astrocytic water and potassium channels in mouse models 310 Acta Neuropathol (2011) 122:293–311 123and humans with Alzheimer’s disease.